Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino? The honest answer is that it can be either.

Central Carolina Community College alumni working in the biotechnology industry took center stage at a recent biotechnology networking event held at the Dennis A. Wicker Civic & Conference Center in ...

Scientists at the Department of Energy's Oak Ridge National Laboratory have created a platform that pinpoints genetic ...

"Biotechnology" is a term commonly applied to the development of new medicines and therapies, the development of genetically modified plants, biofuels, biological treatment, or the production of ...

Microbial biotechnology is a dynamic field, The origins of microbiology can be traced back to the pioneering research by scientists such as Louis Pasteur and Robert Koch in the 19 th century. Within a ...

UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...

Biotechnology is a curious marriage of two seemingly disparate worlds. On one end, we have living organisms—wild, unpredictable celestial creations that can probably never be understood or appreciated ...

Operator: Hello and welcome to Vir Biotechnology's Second Quarter 2026 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. [Operator Instructions] I ...

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...

IASO Biotechnology ('IASO Bio) today announced the completion of its acquisition of MediSix Therapeutics ('MediSix'), a Singapore-based immune cell engineering and cell therapy company.